Fabrinet vs 22nd Century Group Inc — how do they compare? Fabrinet trades at $467 (market cap $17.44B), while 22nd Century Group Inc trades at $4.27 (market cap $1.52M). The key difference: Fabrinet is far larger — about 11473.7× 22nd Century Group Inc's market cap. Which is the better fit depends on your goals.
| FN | XXII | |
|---|---|---|
Market Cap | $17.44B | $1.52M |
Sector | Technology | Technology |
52-Week High | $746.47 | $1.47K |
52-Week Low | $277.04 | $3.90 |
Enterprise Value | $16.50B | -$6.71M |
Signals from Pluang's Aura AI — not financial advice
Fabrinet (FN) trades at $474.19, down 1.78% on the day, with a bearish technical signal despite strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $3.72 exceeding expectations. Analyst consensus remains strongly bullish with a $733 price target, though technical indicators show selling pressure with support at $473 and resistance at $484.
FN presents a compelling growth story driven by AI infrastructure demand, with revenue projected to grow from $3.42B to $4.2B in 2026. However, premium valuation metrics (P/E 41.81, P/B 7.57) and technical bearishness create near-term headwinds. The risk-reward favors long-term investors given the company's strategic positioning in optical communications and debt-free balance sheet.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Fabrinet provides advanced optical and electromechanical manufacturing services to original equipment manufacturers. It specializes in complex products for telecom, automotive, and medical industries.
Read more on FN →22nd Century Group is a plant biotechnology company that uses genetic engineering and gene editing to control the levels of nicotine in tobacco plants. Its flagship product line, VLN®, is the first and only combustible cigarette authorized by the FDA as a Modified Risk Tobacco Product (MRTP), containing 95% less nicotine than traditional cigarettes to help adult smokers smoke less.
Read more on XXII →